Biscayne Pharmaceuticals merges with Insero Health

6 October 2015

USA-based Biscayne Pharmaceuticals and Insero Health are merging to create a combined entity with two different research areas. The two companies already have a common executive chairman at the helm. No financial details were disclosed.

Biscayne Pharmaceuticals is engaged in the development of treatments for cancer and other conditions based on growth hormone-releasing hormone (GHRH) analogs. Insero Health is focused on making treatments for epilepsy, and other central nervous system (CNS) disorders.

Insero Health’s chief executive, Stephen Collins, has become the CEO of Biscayne Pharmaceuticals, while Samuel Reich, co-founder of both Biscayne and Insero Health will remain executive chairman of the combined companies.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK